Table 1_A novel clinical FIT model predicts prognosis of unresectable hepatocellular carcinoma treated with TACE combined with lenvatinib and PD-1 inhibitors therapy.docx

The objective response and disease control rate were 52.5 and 77.7%, respectively. The optimal cut-off point for fibrin degradation products (FDP) and serum iron level were determined as 4.7 μg/dL and 60.0 μg/dL, respectively. Multivariate Cox regression identified FDP, serum iron level and tumor burden score (TBS) as independent predictors of OS, and these clinical parameters established the FIT model.

The FIT model demonstrated favorable discriminative capability for predicting OS with AUC of 0.809 (95% CI: 0.740-0.879) and 0.798 (95% CI: 0.710-0.886) in the training and validation cohorts, respectively. Kaplan-Meier analyses revealed significant prognostic stratification for OS and progression-free survival (PFS) among risk groups defined by FIT model (p < 0.001). Subgroup analyses in alpha-fetoprotein (AFP), tumor number and Barcelona Clinic Liver Cancer (BCLC) stage subsets confirmed the prognostic relevance of FIT model in uHCC.</p>Conclusion<p>The novel clinical FIT model could effectively predict survival of uHCC patients receiving triple therapy, and facilitate prognostic stratification.</p>